<div><div></div><div><span><p><span>Xilio Therapeutics, Inc. reported first-quarter 2026 results with revenue rising to $12.6M and a narrower net loss versus the year-ago quarter. Collaboration and license agreements with AbbVie and Gilead drove revenue growth while higher R&amp;D spending weighed on results.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $12.6M for Q1 2026, compared with $2.9M in the year-ago quarter; YoY change +$9.7M.</span></li><li><span>Net income: Net loss attributable to common stockholders was $(9.5) M for Q1 2026 versus a net loss of $(13.3) M in the year-ago quarter (improved $3.7M YoY).</span></li><li><span>Diluted EPS was $(0.58) for Q1 2026, compared with $(2.49) in the year-ago quarter (improved YoY).</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue growth was driven by collaboration and license revenue from AbbVie and Gilead, which lifted receipts by $9.7M to $12.6M.</span></li><li><span>R&amp;D spending accelerated, increasing by $11.6M, primarily to support IND-enabling manufacturing for XTX501 and expanded preclinical activities.</span></li><li><span>Clinical programs remain active, including ongoing Phase 1/2 and Phase 2 trials for vilastobart and efarindodekin alfa; an AbbVie milestone was achieved in Q2 2026.</span></li><li><span>Liquidity: cash on hand plus the expected AbbVie milestone are expected to fund operations into early 2028; the company noted potential additional liquidity of $36.2M if Series C warrants are exercised.</span></li></ul><p><span>Original SEC Filing: </span>Xilio Therapeutics, Inc. [ XLO ] - 10-Q - May. 12, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ABBV

GILD

<p>Xilio Therapeutics, Inc. reported Q1 2026 revenue of $12.6M, up from $2.9M YoY, with a net loss of $(9.5) M, an improvement from $(13.3) M last year. The revenue increase was driven by collaborations with AbbVie and Gilead, while R&D expenses rose by $11.6M. The company expects to fund operations into early 2028 with current cash and potential Series C warrant exercises. Clinical trials for vilastobart and efarindodekin alfa are ongoing, with a milestone achieved in Q2 2026.</p>

TradingView

Gilead Sciences, Inc.

Abbvie

Gilead Sciences

Xilio Therapeutics

SPDR S&P Biotech

VG Health

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary